<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470937</url>
  </required_header>
  <id_info>
    <org_study_id>9705-34</org_study_id>
    <nct_id>NCT01470937</nct_id>
  </id_info>
  <brief_title>Early Diabetes Intervention Program</brief_title>
  <acronym>EDIP</acronym>
  <official_title>Early Diabetes Intervention Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an evaluation of the effect of acarbose to delay worsening of fasting glucose control
      in early Type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double blind, randomized, placebo-controlled clinical trial of acarbose in subjects with
      type 2 diabetes (an FDA-approved indication). Subjects were identified who had diabetes by
      glucose tolerance test criteria but non-diabetic fasting glucose concentrations. Treatment
      interventions were assessed for their ability to delay worsening of fasting glucose control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of fasting glucose &gt;140 mg/dL</measure>
    <time_frame>From date of randomization until the date of first documented progression or censoring, up to 5 years post randomization</time_frame>
    <description>Fasting plasma glucose was measured quarterly for up to 5 years. Two consecutive measures above 140 mg/dL defined progression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acarbose 100 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo was administered for acarbose 100 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>acarbose 100 mg PO once daily</description>
    <arm_group_label>Acarbose</arm_group_label>
    <other_name>Precose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>acarbose placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting plasma glucose &lt;140 mg/dL

          -  75 g OGTT 2hr glucose &gt;120 mg/dL

          -  BMI &gt; 25 OR history of gestational diabetes mellitus OR family history of type 2
             diabetes

          -  Age at least 25 years

        Exclusion Criteria:

          -  Cancer within 5 years

          -  Chronic infectious disease (HIV, Hepatitis)

          -  CVD event within 6 months

          -  Uncontrolled hypertension or requiring beta blockers or thiazide diuretics for control

          -  elevated AST or ALT

          -  Serum creatinine &gt;1.4 mg/dL (men) or &gt;1.3 mg/dL (women)

          -  TG &gt;600 mg/dL

          -  Known glucosidase intolerance

          -  Inability to comply with protocol requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kieren J Mather, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert V Considine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marian S Kirkman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital GCRC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program. Diabetes Care. 2006 Sep;29(9):2095-101.</citation>
    <PMID>16936159</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>November 10, 2011</last_update_submitted>
  <last_update_submitted_qc>November 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Kieren Mather</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>diabetes acarbose alphaglucosidase prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

